Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.73 |
| ▸ | DDB1 | Q16531 | 16/20 | 0.73 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.53 |
| ▸ | TNF | P01375 | 1/20 | 0.53 |
| ▸ | IL1B | P01584 | 1/20 | 0.53 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.53 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.51 |
| ▸ | NCOR2 | Q9Y618 | 4/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2381344 | 1.00 | CRBN (0.73) | CRBNDDB1BRD4IKZF3TNF | |
| SCHEMBL501757 | 1.00 | CRBN (0.73) | CRBNDDB1BRD4IKZF3TNF | |
| SCHEMBL31563747 | 0.99 | DDB1 (0.75) | CRBNDDB1BRD4IKZF3TNF | |
| SCHEMBL20118479 | 0.93 | DDB1 (0.79) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL1424775 | 0.93 | DDB1 (0.79) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL20118388 | 0.93 | DDB1 (0.79) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL3783534 | 0.92 | CRBN (0.72) | CRBNDDB1BRD4IKZF3TNF | |
| SCHEMBL12250832 | 0.91 | CRBN (0.61) | CRBNDDB1BRD4HDAC3HDAC1 | |
| SCHEMBL24938255 | 0.91 | CRBN (0.70) | CRBNDDB1BRD4IKZF3TNF | |
| SCHEMBL2384336 | 0.91 | CRBN (0.70) | CRBNDDB1BRD4IKZF3TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125449-A1 | ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | JUNO THERAPEUTICS, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12583904-B2 | Articles of manufacture and methods for treatment using adoptive cell therapy | JUNO THERAPEUTICS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4611798-A1 | METHODS OF TREATMENT WITH T CELL THERAPY AND IMMUNOMODULATORY AGENT MAINTENANCE THERAPY | CELGENE CORPORATION (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4543923-A1 | TREATMENT METHODS FOR SECOND LINE THERAPY OF CD19-TARGETED CAR T CELLS | Juno Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| US-20250011387-A1 | ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | JUNO THERAPEUTICS, INC. (US) | 2025-01-09 | — | — | US | disclosed |
| WO-2024097905-A1 | METHODS OF TREATMENT WITH T CELL THERAPY AND IMMUNOMODULATORY AGENT MAINTENANCE THERAPY | CELGENE CORPORATION (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2023250400-A1 | TREATMENT METHODS FOR SECOND LINE THERAPY OF CD19-TARGETED CAR T CELLS | JUNO THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| US-20220324991-A1 | BCMA-BINDING ANTIBODIES AND USES THEREOF | CELGENE CORPORATION | 2022-10-13 | — | — | US | disclosed |
| US-11401336-B2 | BCMA-binding antibodies and uses thereof | CELGENE CORPORATION (US) | 2022-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011387-A1 | ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | ICOS, PBK, BCL6 | CRBN 222/4885DDB1 3053/4885BRD4 1761/4885 |
| US-20220324991-A1 | BCMA-BINDING ANTIBODIES AND USES THEREOF | CD79B, BCL6, CD22 | CRBN 401/4885DDB1 378/4885BRD4 452/4885 |
| US-11401336-B2 | BCMA-binding antibodies and uses thereof | CD79B, BCL6, CD22 | CRBN 401/4885DDB1 378/4885BRD4 452/4885 |
| US-12583904-B2 | Articles of manufacture and methods for treatment using adoptive cell therapy | CD4, CD2, ICOS | CRBN 758/4885DDB1 4105/4885BRD4 3628/4885 |
| US-20260125449-A1 | ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | MALT1, BCL9, ICOS | CRBN 134/4885DDB1 4720/4885BRD4 2982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.